IL6 and nonpapillary renal cell carcinoma: GSEA further validated that CCNA2 could activate E2F targets, interferon alpha response, IL6-JAK-STAT signaling, interferon gamma response, Myc targets, G2M checkpoint, and inflammatory response while inhibit fatty acid metabolism and bile acid metabolism pathways in ccRCC (Figure 7(d)).